Cowen and BMO are the joint bookrunners; Wedbush Securities to assist
By Devika Patel
Knoxville, Tenn., Oct. 1 - Fate Therapeutics, Inc. said it priced its $40 million initial public offering of stock with a $6 million greenshoe. The deal was announced Aug. 14.
The company will sell 6,666,667 common shares at $6.00 per share.
Cowen and Co., LLC and BMO Capital Markets Corp. are the joint bookrunning managers.
Proceeds will be used for research and development activities, working capital and general corporate purposes.
The clinical-stage biopharmaceutical company is based in San Diego. The company intends to list its common stock on the Nasdaq under the symbol "FATE."
| Issuer: | Fate Therapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $40 million
|
| Greenshoe: | $6 million
|
| Shares: | 6,666,667
|
| Price: | $6.00
|
| Warrants: | No
|
| Bookrunners: | Cowen and Co., LLC and BMO Capital Markets Corp.
|
| Co-manager: | Wedbush Securities Inc.
|
| Announcement date: | Aug. 14
|
| Pricing date: | Oct. 1
|
| Settlement date: | Oct. 4
|
| Stock exchange: | Nasdaq: FATE
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
